BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO): 18 pipeline candidates · 5 upcoming catalysts · ~16 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.6 months
D/E -1.60 · 0% dilution
Lead: Approved
18 candidates
5 upcoming, next in ~697d
0 buys · 96 sells (180d)
A transparent, data-derived signal for BridgeBio Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.2B
Cash
$882.0M
Quarterly Burn
$197.3M
Runway
15.6 mo
Revenue
$194.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| acoramidis (AG10) | Phase 3 |
| attruby | Approved |
| Attruby / Beyonttra (acoramidis) | Approved |
| BBO-10203 | Phase 1 |
| BBO-11818 | Phase 1 |
| BBP-418 | Phase 3 |
| Cetuximab | Phase 1 |
| FOLFOX | Phase 1 |
| infigratinib | Phase 3 |
| Infigratinib (low-dose) | Phase 3 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
460
Total value held
$15.04B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 26,358,026 | $1.96B |
| vanguard capital management llc | 15,518,990 | $1.15B |
| blackrock, inc. | 14,207,757 | $1.06B |
| viking global investors lp | 11,842,434 | $879.4M |
| farallon capital management llc | 9,365,463 | $695.5M |
| vanguard portfolio management llc | 8,080,573 | $600.1M |
| ubs group ag | 5,890,321 | $437.4M |
| geode capital management, llc | 4,918,030 | $371.9M |
| jane street group, llc | 4,935,272 | $366.5M |
| state street corp | 4,934,320 | $366.4M |
Showing top 10 of 460 institutional holders of BridgeBio Pharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BridgeBio Pharma, Inc.'s pipeline?
BridgeBio Pharma, Inc. (BBIO) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BridgeBio Pharma, Inc.'s lead drug candidate?
BridgeBio Pharma, Inc.'s most advanced tracked candidate is acoramidis (AG10) (Phase 3) for Amyloidosis.
What is BridgeBio Pharma, Inc.'s next catalyst?
BridgeBio Pharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Sympto" — expected May 15, 2028.
What is BridgeBio Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BridgeBio Pharma, Inc. has approximately 15.6 months of cash runway.
What is BridgeBio Pharma, Inc.'s market capitalization?
BridgeBio Pharma, Inc.'s market capitalization is approximately $13.2B.
Get the full picture on BridgeBio Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.